STOCK TITAN

Structure Therapeutics (GPCR) exec sells 3,939 ADSs under plan

(Moderate)
(Negative)
Form Type
4

Rhea-AI Filing Summary

Structure Therapeutics Inc. (GPCR) reported insider activity by Chief Scientific Officer Xichen Lin involving option exercises, ADS conversions, and sales on 2026-08-18. Lin exercised options for 11,817 Ordinary Shares at $0.34 per share, which were converted into 3,939 American Depositary Shares (ADSs). All 3,939 ADSs were then sold in three tranches at weighted average prices of $53.133, $54.197, and $55.05 per ADS under a Rule 10b5-1 trading plan adopted on March 26, 2026. Following the partial exercise, 142,898 Ordinary Shares remain subject to the option.

Positive

  • None.

Negative

  • None.
Insider Lin Xichen
Role CHIEF SCIENTIFIC OFFICER
Sold 3,939 shs ($211K)
Type Security Shares Price Value
Exercise Share Option (right to buy) F1, F3, F4 11,817 $0.00 $0.00
Conversion American Depositary Shares F5, F6 3,939 $0.00 $0.00
Sale American Depositary Shares F5, F7, F8, F9 3,020 $53.133 $160K
Sale American Depositary Shares F5, F7, F8, F10 519 $54.197 $28K
Sale American Depositary Shares F5, F7, F8, F11 400 $55.05 $22K
Exercise Ordinary Shares F1 11,817 $0.34 $4K
Conversion Ordinary Shares F2 11,817 $0.00 $0.00
Holdings After Transaction: Share Option (right to buy) — 142,898 shares (Direct); American Depositary Shares — 0 shares (Direct); Ordinary Shares — 228,960 shares (Direct)
Footnotes (11)
  1. F1. Reflects price per share in Ordinary Shares.
  2. F2. The Ordinary Shares were converted into American Depositary Shares as reported in Table II.
  3. F3. 1/4 of the Ordinary Shares vested one year after July 22, 2019 (the "Vesting Commencement Date"); the balance of the Ordinary Shares vested in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.
  4. F4. This reflects the number of Ordinary Shares remaining under the share option following the partial exercise of the share option for 11,817 Ordinary Shares.
  5. F5. Each American Depositary Share is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The American Depositary Shares have no expiration date.
  6. F6. 11,817 Ordinary Shares, which were acquired upon exercise of a share option, were converted into 3,939 American Depositary Shares.
  7. F7. The American Depositary Shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 26, 2026.
  8. F8. Reflects price per share in American Depositary Shares.
  9. F9. The weighted average sale price for the transaction reported was $53.133 and the range of prices were between $52.77 and $53.70. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of American Depositary Shares sold at each price will be provided.
  10. F10. The weighted average sale price for the transaction reported was $54.1970, and the range of prices were between $53.80 and $54.7950. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of American Depositary Shares sold at each price will be provided.
  11. F11. The weighted average sale price for the transaction reported was $55.05 and the range of prices were between $54.85 and $55.15. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of American Depositary Shares sold at each price will be provided.
Options Exercised 11,817 Ordinary Shares Shares acquired by Lin on 2026-08-18 through option exercise
Exercise Price $0.34 per Ordinary Share Exercise price for the 11,817 Ordinary Shares
ADS Conversion Ratio 1 ADS : 3 Ordinary Shares Each ADS is convertible into three Ordinary Shares of the issuer
ADSs Sold 3,939 ADSs Total ADSs sold by Lin on 2026-08-18
Sale Price Tranche 1 $53.133 per ADS Weighted average price; range $52.77–$53.70 for 3,020 ADSs
Sale Price Tranche 2 $54.1970 per ADS Weighted average price; range $53.80–$54.7950 for 519 ADSs
Sale Price Tranche 3 $55.05 per ADS Weighted average price; range $54.85–$55.15 for 400 ADSs
Remaining Option Shares 142,898 Ordinary Shares Ordinary Shares remaining under the option after partial exercise
Rule 10b5-1 trading plan regulatory
"The American Depositary Shares were sold pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
American Depositary Shares financial
"Each American Depositary Share is convertible at any time, at the holder's election"
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.
Ordinary Shares financial
"Each American Depositary Share is convertible at any time, at the holder's election, into three Ordinary Shares"
Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.
Vesting Commencement Date financial
"1/4 of the Ordinary Shares vested one year after July 22, 2019 (the "Vesting Commencement Date")"
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

FAQ

What insider transactions did GPCR executive Xichen Lin report on August 18, 2026?

Xichen Lin reported exercising options for 11,817 Ordinary Shares, converting them into 3,939 ADSs, and selling all 3,939 ADSs in three transactions on August 18, 2026, while retaining a substantial remaining option position.

At what prices did GPCR’s Xichen Lin sell American Depositary Shares on this Form 4?

Lin sold 3,939 ADSs in three tranches at weighted average prices of $53.133, $54.197, and $55.05 per ADS. Footnotes disclose price ranges for each tranche and offer detailed breakdowns upon request.

How many Structure Therapeutics (GPCR) shares did Xichen Lin acquire through option exercise?

Lin exercised options covering 11,817 Ordinary Shares at an exercise price of $0.34 per share. These Ordinary Shares were then converted into 3,939 ADSs, each ADS representing three Ordinary Shares of Structure Therapeutics.

Does the GPCR Form 4 indicate a Rule 10b5-1 trading plan for Xichen Lin’s sales?

Yes. The filing indicates the sales of ADSs were made under a Rule 10b5-1 trading plan entered into on March 26, 2026, and the plan-status checkbox is affirmed, indicating pre-arranged trading instructions.

What option position does GPCR’s Xichen Lin retain after these transactions?

After partially exercising his option, Lin still has 142,898 Ordinary Shares remaining under the same share option. The footnotes clarify this balance reflects the position following the 11,817-share partial exercise reported.

What is the ADS-to-Ordinary Share conversion ratio for GPCR in this Form 4?

Each GPCR American Depositary Share is convertible into three Ordinary Shares. The Form 4 states that 11,817 Ordinary Shares acquired via option exercise were converted into 3,939 ADSs using this 3:1 conversion ratio.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lin Xichen

(Last)(First)(Middle)
C/O STRUCTURE THERAPEUTICS INC.
601 GATEWAY BLVD., SUITE 900

(Street)
SOUTH SAN FRANCISCO CALIFORNIA 94080

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Structure Therapeutics Inc. [ GPCR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CHIEF SCIENTIFIC OFFICER
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/18/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Ordinary Shares08/18/2026M11,817A$0.34(1)240,777D
Ordinary Shares08/18/2026C11,817(2)D$0228,960D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Share Option (right to buy)$0.34(1)08/18/2026M11,817 (3)09/10/2029Ordinary Shares11,817$0142,898(4)D
American Depositary Shares(5)08/18/2026C3,939(6) (5) (5)Ordinary Shares11,817$03,939D
American Depositary Shares(5)08/18/2026S(7)3,020 (5) (5)Ordinary Shares9,060$53.133(8)(9)919D
American Depositary Shares(5)08/18/2026S(7)519 (5) (5)Ordinary Shares1,557$54.197(8)(10)400D
American Depositary Shares(5)08/18/2026S(7)400 (5) (5)Ordinary Shares1,200$55.05(8)(11)0D
Explanation of Responses:
1. Reflects price per share in Ordinary Shares.
2. The Ordinary Shares were converted into American Depositary Shares as reported in Table II.
3. 1/4 of the Ordinary Shares vested one year after July 22, 2019 (the "Vesting Commencement Date"); the balance of the Ordinary Shares vested in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.
4. This reflects the number of Ordinary Shares remaining under the share option following the partial exercise of the share option for 11,817 Ordinary Shares.
5. Each American Depositary Share is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The American Depositary Shares have no expiration date.
6. 11,817 Ordinary Shares, which were acquired upon exercise of a share option, were converted into 3,939 American Depositary Shares.
7. The American Depositary Shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 26, 2026.
8. Reflects price per share in American Depositary Shares.
9. The weighted average sale price for the transaction reported was $53.133 and the range of prices were between $52.77 and $53.70. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of American Depositary Shares sold at each price will be provided.
10. The weighted average sale price for the transaction reported was $54.1970, and the range of prices were between $53.80 and $54.7950. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of American Depositary Shares sold at each price will be provided.
11. The weighted average sale price for the transaction reported was $55.05 and the range of prices were between $54.85 and $55.15. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of American Depositary Shares sold at each price will be provided.
/s/ Jun Yoon, Attorney-in-Fact08/19/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)